ReviewThe Korean journal of helicobacter and upper gastrointestinal research2024
Performance of the National Cancer Screening Program for Gastric Cancer in Korea.
Review in The Korean journal of helicobacter and upper gastrointestinal research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Efficacy and safety of a novel ClearHemograsper for gastric endoscopic submucosal dissection: A prospective randomized controlled trial.Scientific reports · 2026Trial
- Increased Heart Failure Risk with Gastric Cancer Progression: A Nationwide Population-Based Cohort Study.Gut and liver · 2026Article
- Nationwide Survey on Endoscopic Submucosal Dissection for Early Gastric Cancer in Korea: Results From the Korean College ofJournal of gastric cancer · 2026Review
- Nationwide Survey on Endoscopic Submucosal Dissection for Early Gastric Cancer in Korea: Results From the Korean College of Helicobacter and Upper Gastrointestinal Research (KCHUGR) 2023 Survey.The Korean journal of helicobacter and upper gastrointestinal research · 2026Article
- Commentary: 1-year risks of cancers associated with COVID-19 vaccination: a large population-based cohort study in South Korea.Frontiers in public health · 2026Article
- SHAP-explained machine-learning model for high-risk gastric cancer identification.Frontiers in oncology · 2026Article
- Endoscopic Diagnosis of Remnant Gastric Cancer After Gastrectomy.The Korean journal of helicobacter and upper gastrointestinal research · 2025Review
- Prognostic Value of the Level of Urine Dipstick Proteinuria in Gastric Cancer in the Korean Population.Cancers · 2025Article
- The Cost-Effectiveness of Adding Helicobacter Pylori Screening to the National Gastric Cancer Screening Program in Korea: Protocol for a Cost-Effectiveness Modeling Study.JMIR research protocols · 2025Article
- Stomach Cancer Screening in Japan and Korea.The Korean journal of helicobacter and upper gastrointestinal research · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In Korea, the National Cancer Screening Program for Gastric Cancer (NCSP-GC) was implemented in 1999 to reduce the mortality associated with gastric cancer, the most common cancer in Korea until 2018. In 2021, approximately 7.76 million screening endoscopies were performed as part of the NCSP-GC, including 10664 participants (37.2% of the total gastric cancer cases in 2021; 10909 of the 29361 cases) with histologically confirmed gastric cancer, according to data from the Korean National Health Insurance Service. The endoscopic screening component of the NCSP-GC has contributed to the early detection of gastric cancer and the reduction of its mortality. This review evaluates the performance and limitations of the endoscopic screening component of the NCSP-GC and discusses strategies to overcome limitations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.